Out-patient antihypertensive drug utilization and stroke mortality: An ecological study

European Journal of Public Health

Volumn 6, Issue 2, 1996, Pages 113-117

  Merlo, J ^a,d   Rastam L ^a   Ranstam, J ^b   Wessling, A ^c   Melander, A ^b  

^a LUND UNIVERSITY   (Sweden)

^b Network for Pharmacoepidemiology Foundation   (Sweden)

^c National Corporation of Pharmacies   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Drug utilization; Ecological study; Effectiveness; Hypertension; Regional differences; Stroke

Indexed keywords

EID: 0041621290     PISSN: 11011262     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurpub/6.2.113     Document Type: Article

References (28)

1. Swedish Drug Statistics. The diagnosis-prescription survey. Stockholm: Apoteks̀bolaget, 1993 (Swedish).
2. Hypertension Detection and Follow-up Program (HDFP) Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. III: reduction in stroke incidence among persons with high blood pressure. JAMA 1979;242:2572-7.
3. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomised controlled trials. Prog Cardiovasc Dis 1986;29(3)(Suppl):99-118.
4. SHEP Cooperative Research Group. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1982;265:3255-64.
5. Dahlōf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester P. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-hypertension). Lancet 1991;338:1281-5.
6. Casper M, Wing S, Strogatz D, Davis CE, Tyroler HA. Antihypertensive treatment in US trends in stroke mortality, 1962 to 1980. Am J Public Hlth 1992;82:1600-6.
7. Bonita R, Beaglehole R. Cerebrovascular disease: explaining stroke mortality trends. Lancet 1993;341:1510-1.
8. Lunde PKM, Baksaas I. Epidemiology of drug utilization: basic concepts and methodology. Acta Med Scand Suppl 1986;1:7-11.
9. Baksaas I. Patterns in drug utilization: national and international aspects: antihypertensive drugs. Acta Med Scand Suppl 1984;683:59-66.
10. Hjort PF. Relation between drug utilization and morbidity pattern: antihypertensive drugs. Acta Med Scand Suppl 1984;683:89-93.
11. Westerholm B, Agenäs I, Dahlström B A, Nordenstam I. Relation between drug utilization and morbidity pattern. Acta Med Scand Suppl 1984;683:95-9.
12. Wiholm BE, Westerholm B. Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. Acta Med Scand Suppl 1984;683:107-17.
13. Boethius G. Approaches to assessing the rationality of drug usage in a developed country. Acta Med Scand Suppl 1986;721:21-6.
14. Öreberg M, Jonsson G, West K, Eberhard-Grahn M, Råstam L, Melander A. Large inter-community differences in cardiovascular drug consumption: relation to mortality, risk factors and socioeconomic differences. Eur J Clin Pharmacol 1992;43:449-54.
15. Capellà D, Porta M, Laporte JR. Utilization of antihypertensive drugs in certain European countries. Eur J Clin Pharmacol 1983;25:431-5.
16. Hense HW, Tennis P. Changing patterns of antihypertensive drug use in a German population between 1984 and 1987: results of a population based cohort study in the Federal Republic of Germany. Eur J Clin Pharmacol 1990;39:1-7.
17. Nerbrand C. Traditional risk-factors profile fails to explain striking geographical differences in IHD mortality among middle-aged men: the project 'myocardial infarction in mid Sweden'. Scand J Prim Health Care 1992;10:111-7.
18. Merlo J, Ranstam J, Råstam L, Wessling A, Melander A. Age standardisation of drug utilisation: comparisons of different methods using cardiovascular drug data from Sweden and Spain. Eur J Clin Pharmacol 1994;46:393-8.
19. Wessling A. The National Prescription Survey: a data base for drug utilization studies in Sweden: results and experiences from the 1970s and 1980s [dissertation]. Stockholm, Sweden: Stockholm University, 1990.
20. Capellà D. Descriptive tools and analysis. In: Dukes MNG, editor. Drug utilisation studies: methods and uses. WHO regional publication. European series; No. 45. Copenhagen: WHO Regional Office for Europe, 1993:55-78.
21. Yule GU. On some points relating to vital statistics, more specially statistics of occupational mortality. J R Stat Soc 1934;97:1-84.
22. Day NE. A new measure of age standardized incidence: the cumulative rate. In: Waterhouse JAH, Muir CS, Correa P, Powell J, editors. Cancer incidence in five continents, Vol III. IARC Scientific Publication No. 15. Lyon: International Agency for Research on Cancer, 1976:443-52.
23. Kannel WB. Epidemiology of essential hypertension: the Framingan experience. Proceedings of the Royal College of Physicians of Edinburgh, Edinburgh 1991;21:273-87.
24. Lindblad U, Råstam L, Rydén L, Ranstam J, Berglund G, Isacsson SO. Reduced stroke incidence with structured hypertension care: the Skaraborg hypertension project. J Hypertens 1990;8:1147-53.
25. Lindblad U. The prognosis of hypertension: the Skaraborg hypertension project [dissertation]. Malmö, Sweden: Lund University. 1993.
26. Nordic Statistics of Medicines 1990-1992. NLN publication No 34. Nordic Council of Medicines. Uppsala, 1993.
27. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
28. Råstam L, Berglund G, Isacsson S-O, Rydén L. The Skaraborg hypertension project. I: the prevalence of hypertension. Acta Med Scand 1986;219:243-8.